CN102178753A - Medicinal preparation with effects of clearing heat, purging intense heat, detonicating, eliminating blood stasis, cooling blood and stopping bleeding - Google Patents
Medicinal preparation with effects of clearing heat, purging intense heat, detonicating, eliminating blood stasis, cooling blood and stopping bleeding Download PDFInfo
- Publication number
- CN102178753A CN102178753A CN 201110089276 CN201110089276A CN102178753A CN 102178753 A CN102178753 A CN 102178753A CN 201110089276 CN201110089276 CN 201110089276 CN 201110089276 A CN201110089276 A CN 201110089276A CN 102178753 A CN102178753 A CN 102178753A
- Authority
- CN
- China
- Prior art keywords
- extract
- radix
- rhizoma
- radix scutellariae
- rhizoma rhei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a medicinal preparation with the effects of clearing heat, purging intense heat, detonicating, eliminating blood stasis, cooling blood and stopping bleeding. The medicinal unit preparation comprises the following active medicinal ingredients by weight: 0.33 to 0.033 gram of golden thread extract of golden thread, 1 to 0.1 gram of rhubarb extract of rhubarb and 0.5 to 0.05 gram of baical skullcap root extract of baical skullcap root, wherein a weight ratio of golden thread to rhubarb to baical skullcap root is 0.66:2:1, the weight of baicalin serving as an active ingredient in the unit preparation is 6.0 percent higher than that of baical skullcap root, the total weight of frangula emodin and chrysophanol is 0.10 percent higher than the weight of rhubarb, the weight of berberine is 3.03 percent higher than that of golden thread, and the medicinal preparation is prepared from the active medicinal ingredients and pharmaceutically-acceptable auxiliary additive ingredients. Experiments prove that the comprehensive anti-inflammatory, antiviral and purgative effects of the purgation medicinal preparation is obviously superior to those of the conventional contrast medicaments of yiqing capsules, so the resources of natural medicaments are saved, and the curative effect is improved.
Description
Technical field
The present invention relates to a kind of traditional Chinese compound medicine preparation, particularly to the improvement of the pharmaceutical preparation with clearing away heat-fire detoxifcation and blood stasis dispelling cooling blood for hemostasis effect of present use.
Background technology
Radix Et Rhizoma Rhei, Rhizoma Coptidis, Radix Scutellariae are the three highly seasoned Chinese medicine medicines of wanting.Study knownly, its main active substances is respectively that emodin and chrysophanol are that anthraquinone component, the berberine (or its hydrochlorate) of representative is the flavones ingredient of representative for the alkaloids composition of representative, baicalin.Classical Chinese medicine name side " XIEXIN TANG " by Radix Et Rhizoma Rhei, Rhizoma Coptidis, Radix Scutellariae three flavor Chinese medicines are formed is extensive use of clinical.As the YIQING KELI of Chinese medicine finished product preparation and a clearing capsule etc., all has heat-clearing and toxic substances removing, the pathogenic fire purging relieving constipation, effects such as antibiotic, antiinflammatory, antiviral, can be widely used in comprising fever of the body agitation, conjunctival congestion aphtha, throat gingival swelling and pain, constipation, haematemesis, spitting of blood, epistaxis, hemorrhoidal bleeding, pharyngitis, tonsillitis, gingivitis, acute gastroenteritis, dysentery and on exhale multiple treatment of diseases such as antibacterial and viral infection, recorded by Chinese Pharmacopoeia one one of version in 2010.Wherein, consisting of of one clearing capsule preparation: Rhizoma Coptidis 660g, Radix Et Rhizoma Rhei 2000g, Radix Scutellariae 1000g, three flavor medical materials decoct with water respectively twice, 1.5 hours for the first time, 1 hour for the second time, collecting decoction, filter, filtrate is concentrating under reduced pressure respectively, spray drying, and powder is soaked in the mixing that makes Radix Scutellariae extractum powder and Radix Et Rhizoma Rhei and Rhizoma Coptidis; Two kinds of extract powders are made granule respectively, and drying is pulverized, and adding starch, Pulvis Talci and magnesium stearate are an amount of, and mixing incapsulates, and makes 1000, promptly.Every dress of this product 0.5g, every contains baicalin 〉=30.0mg, contains emodin and chrysophanol total amount 〉=0.70mg; Oral, one time 2,3 times on the one.
Because the effective medicinal ingredient that uses in the above-mentioned clearing capsule is to adopt by traditional approach directly to be fed intake by medical material or decoction pieces, decocts with water resulting extract.Test shows that its extract yield and extraction ratio of effective constituents are low, have caused the utilization rate of medical material low, have wasted natural pharmaceutical resources.
Summary of the invention
At above-mentioned situation, the invention provides a kind of pharmaceutical preparation of improved form with clearing away heat-fire detoxifcation and blood stasis dispelling cooling blood for hemostasis effect, make it can obviously be better than a clearing capsule that uses at present, thereby can save natural pharmaceutical resources greatly, and can also improve curative effect.
The present invention has the pharmaceutical preparation of clearing away heat-fire detoxifcation and blood stasis dispelling cooling blood for hemostasis effect, be that effective medicinal ingredient in every pharmaceutical units preparation is for by the Rhizoma Coptidis extract of 0.33～0.033g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 1～0.1g Radix Et Rhizoma Rhei, 0.5 the Radix Scutellariae extract of～0.05g Radix Scutellariae, and Rhizoma Coptidis, Radix Et Rhizoma Rhei, the part by weight of Radix Scutellariae is 0.66: 2: 1, and 6.0% of the weight of effective ingredient baicalin in this unit formulation 〉=its Radix Scutellariae weight, 0.10% of the total amount of emodin and chrysophanol 〉=its Radix Et Rhizoma Rhei weight, 3.03% of the weight of berberine 〉=its Rhizoma Coptidis weight is formed jointly with the auxiliary adding ingredient of acceptable in the medicine.
Said medicine preparation of the present invention is preferably the Peroral solid dosage form type pharmaceutical preparation that comprises tablet, capsule, soft capsule, drop pill.Therefore the implication of said unit formulation is meant every tablet of medicine in the tablet, or in the capsule, soft capsule preparation every is than capsule, or every drop pill in the dropping pill formulation.
For example, effective medicinal ingredient in the said every pharmaceutical units preparation of said medicine preparation of the present invention, can be for by the Rhizoma Coptidis extract of 0.33g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 1g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.5g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=30mg, emodin and chrysophanol total amount 〉=1.0mg, berberine 〉=10mg.
It also can be the effective medicinal ingredient in said every pharmaceutical units preparation, for by the Rhizoma Coptidis extract of 0.165g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 0.5g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.25g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=15mg, emodin and chrysophanol total amount 〉=0.5mg, berberine 〉=5mg.
It can also be the effective medicinal ingredient in said every pharmaceutical units preparation, for by the Rhizoma Coptidis extract of 0.066g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 0.2g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.1g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=6mg, emodin and chrysophanol total amount 〉=0.2mg, berberine 〉=2mg.
It can also be the effective medicinal ingredient in said every pharmaceutical units preparation, for by the Rhizoma Coptidis extract of 0.033g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 0.1g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.05g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=3mg, emodin and chrysophanol total amount 〉=0.1mg, berberine 〉=1mg.
Said effective medicinal ingredient in the said medicine preparation of the present invention, preferably be adopted as the extract for preparing in the following manner: containing pure ratio with volume is 0～80% ethanol-water mixed solvent, pulverize separately is crossed 5～60 mesh sieves (after the said proportional quantities Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae that is equivalent to sieve aperture internal diameter 4～0.25mm) extract, through concentrating under reduced pressure and dried extract.Said concentrating under reduced pressure and/or drying under reduced pressure, according to present technological requirement and regulation, its operative temperature generally can be above 75 ℃.Wherein said drying except that adopting drying under reduced pressure, also can adopt spray drying commonly used at present.
Above-mentioned said effective medicinal ingredient, being more preferably employing, to contain pure ratio by volume be 50～80% ethanol, after Rhizoma Coptidis, Radix Et Rhizoma Rhei, the Radix Scutellariae that pulverize separately is crossed the said proportional quantities of 5～60 mesh sieves extracts, through concentrating under reduced pressure and exsiccant extract.
In addition, above-mentioned said effective medicinal ingredient can also be respectively the corresponding extract for preparing by in following concrete mode:
Respectively to Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae with said extraction solvent heating and refluxing extraction 2～3 times, each 0.5～2 hour, merge extractive liquid, filtered, filtrate is respectively through concentrating under reduced pressure and dry Radix Scutellariae extract, Radix Et Rhizoma Rhei extract and the Rhizoma Coptidis extract that obtains.Wherein, when being when extracting solvent with water, said heating and refluxing extraction promptly is equal to conventional decoction and extracts.Because in pharmaceuticals industry, said to decoct with water with adding the water heating and refluxing extraction be to have identical implication and effect.
Radix Scutellariae extract in said effective medicinal ingredient, for with the pulverizing Radix Scutellariae water boiling and extraction of said proportional quantities 2～3 times, each 0.5～2 hour, collecting decoction filters, regulate pH value to 1～2 with hydrochloric acid behind the concentrating under reduced pressure, left standstill 2-12 hour in 70～90 ℃, filter, precipitate the extract that water, ethanol successively are washed till pH value to 5～7 after drying;
Rhizoma Coptidis extract and Radix Et Rhizoma Rhei extract in said effective medicinal ingredient after Rhizoma Coptidis and Radix Et Rhizoma Rhei after the pulverizing of said proportional quantities are extracted with 0～80% ethanol-water solution percolation respectively, are collected percolate, concentrating under reduced pressure and dried extract.
With the above-mentioned Radix Et Rhizoma Rhei that obtains, Rhizoma Coptidis, Radix Scutellariae extract as effective medicinal ingredient, the corresponding oral drug preparation that is prepared from the conventional auxiliary adding ingredient of acceptable in the oral drugs.For example, with can received disintegrating agent in oral formulations, after auxiliary interpolation composition that excipient, lubricant, binding agent, filler etc. are commonly used mixes, handle the oral drugs of solid preparation forms such as the slow releasing agent of the tablet of making, pill, granule, capsule, soft capsule or appropriate format, controlled release agent by corresponding common process method.
Wherein, filler can comprise as starch commonly used, dextrin, Icing Sugar, pregelatinized Starch, lactose, glucose, microcrystalline Cellulose, calcium carbonate, calcium sulfate, calcium bicarbonate etc.;
Adhesive can comprise as hypromellose commonly used, polyvidone, starch slurry, dextrin slurry, syrup, rubber cement, sodium alginate, Polyethylene Glycol, Resina persicae, arabic gum etc.;
Disintegrating agent can comprise as cross-linking sodium carboxymethyl cellulose commonly used, polyvinylpolypyrrolidone, carboxymethyl starch sodium, hydroxypropyl starch, low-substituted hydroxypropyl cellulose citric acid, tartaric acid, anhydride, sodium bicarbonate, sodium carbonate etc.;
The lubricating value agent can comprise as magnesium stearate (sodium) commonly used, Pulvis Talci, micropowder silica gel, liquid paraffin, Polyethylene Glycol etc.;
Substrate in the soft capsule can comprise as vegetable oil (as salad oil, Oleum Ricini, hydrogenated soybean wet goods), Polyethylene Glycol (as PEG 300, PEG 400, PEG 6000 etc.) commonly used; And antioxidants such as sodium sulfite commonly used, sodium sulfite, sodium pyrosulfite, sodium thiosulfate, ascorbic acid, cysteine, butylated hydroxyarisol, two fourth cresols, vitamin E;
Blocker in the oral sustained-release preparation can comprise as Cera Flava commonly used, Brazil wax, hydrogenated vegetable oil, stearyl alcohol, glyceryl monostearate, the cellulose acetate phthalate ester, L-or S-acrylic resin, the hypromellose phthalate ester, Hydroxypropyl Methyl Cellulose Phthalate, methylcellulose, sodium carboxymethyl cellulose, hypromellose, polyvidone, carbopol, sodium alginate, chitosan, ethyl cellulose, polymethacrylates, non-toxic polyvinyl chloride, polyethylene, ethylene-vinyl acetate copolymer, silicone rubber; And as thickening agent commonly used such as gelatin, polyvidone, sodium carboxymethyl cellulose, polyvinyl alcohol, dextran.These conventional auxiliary adding ingredients that use can be selected to use according to different preparations and/or needs.
Result of the test shows, the described pharmaceutical preparation of adopting the above-mentioned preparation method of the present invention to obtain, on the basis of the consumption that significantly reduces medical material, can not only meet or exceed a former clearing capsule extract and a content of effective, and can have equal or more excellent drug action, produced beyond thought effect economizing on resources and give full play to aspects such as drug action.
The specific embodiment by the following examples is described in further detail foregoing of the present invention again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.Do not breaking away under the above-mentioned technological thought situation of the present invention, various replacements or change according to ordinary skill knowledge and customary means are made all should comprise within the scope of the invention.
The specific embodiment
Embodiment 1
Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae were pulverized 5 mesh sieves, take by weighing Rhizoma Coptidis 330g, Radix Et Rhizoma Rhei 1000g, Radix Scutellariae 500g, decoct with water respectively 2 times, add for the first time 14 times in water, add 12 times in water for the second time, decocted 0.5～1 hour at every turn, collecting decoction, filter, filtrate is concentrating under reduced pressure respectively, and spray drying obtains Radix Scutellariae extract and Radix Et Rhizoma Rhei and Rhizoma Coptidis extract.The said extracted thing adds right amount of auxiliary materials such as starch, mix homogeneously, and processed incapsulates according to a conventional method, makes 1000, every dress 0.5g.Press method of Chinese Pharmacopoeia version in 2010, adopt the HPLC method to measure content of effective, every capsules contains baicalin 35.2mg, emodin and chrysophanol total amount 1.3mg, berberine 14mg.
Embodiment 2
Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae were pulverized 60 mesh sieves, take by weighing Rhizoma Coptidis 165g, Radix Et Rhizoma Rhei 500g, Radix Scutellariae 250g, add 70% alcohol reflux 3 times respectively, for the first time add 8 times, for the second time and respectively add 6 times for the third time, extracted 0.5～1 hour at every turn, merge extractive liquid,, filter, filtrate is reclaim under reduced pressure, concentrated respectively, and drying obtains Radix Scutellariae, Radix Et Rhizoma Rhei, Rhizoma Coptidis extract.The said extracted thing adds right amount of auxiliary materials such as starch, mix homogeneously, processed according to a conventional method, incapsulate, make 1000, every dress 0.25g adopts the HPLC method to measure content of effective, and every capsules contains baicalin 19.1mg, emodin and chrysophanol total amount 1.76mg, berberine 7.9mg.
Embodiment 3
Rhizoma Coptidis was pulverized 50 mesh sieves, took by weighing Rhizoma Coptidis 660g, with 50% alcohol reflux 2 times, added 12 times for the first time, refluxed 2 hours, added 10 times for the second time, refluxed 1 hour, and merge extractive liquid, filters, and filtrate decompression concentrates, and drying obtains Rhizoma Coptidis extract.Radix Et Rhizoma Rhei was pulverized 10 mesh sieves, took by weighing Radix Et Rhizoma Rhei 2000g, used 80% ethanol percolate extraction, collected percolate 8-10L, and reclaim under reduced pressure concentrates, and drying obtains Radix Et Rhizoma Rhei extract.Radix Scutellariae was pulverized 20 mesh sieves, took by weighing Radix Scutellariae 1000g, decocted with water 3 times (boiling water feeds intake), add for the first time 10 times in water, decocted 2 hours, add 8 times in water for the second time and for the third time respectively, decocted collecting decoction 1 hour, filter, filtrate is concentrated into about 4L, regulates pH value to 1～2,80 ℃ insulation, leaves standstill 2-12 hour with hydrochloric acid, filter, precipitation is washed till pH value to 5～7 with suitable quantity of water, 50-95% ethanol successively, and drying promptly gets Radix Scutellariae extract.
The said extracted thing adds right amount of auxiliary materials such as starch, mix homogeneously, processed according to a conventional method, tabletting, coating, make 10000, adopt the HPLC method to measure content of effective, every contains baicalin 7.2mg, emodin and chrysophanol total amount 0.6mg, berberine 2.9mg.
Embodiment 4
Rhizoma Coptidis was pulverized 20 mesh sieves, took by weighing Rhizoma Coptidis 330g, decocted with water 3 times, added for the first time 10 times in water, decocted 1.5 hours, for the second time and add 8 times in water for the third time, decocted 1 hour, and collecting decoction filters, and filtrate decompression is concentrated, and drying obtains Rhizoma Coptidis extract.Radix Et Rhizoma Rhei was pulverized 20 mesh sieves, took by weighing Radix Et Rhizoma Rhei 1000g, with 50% alcohol reflux 3 times, added 10 times of amounts, backflow 1 hour for the first time, for the second time and respectively add 8 times, 6 times amounts for the third time, refluxed merge extractive liquid, 0.5 hour, filter, filtrate decompression reclaims, concentrates, and drying obtains Radix Et Rhizoma Rhei extract.Radix Scutellariae was pulverized 40 mesh sieves, took by weighing Radix Scutellariae 500g, decocted with water 2 times (boiling water feeds intake), add for the first time 14 times in water, decocted 1 hour, add 12 times in water for the second time, decocted collecting decoction 0.5 hour, filter, filtrate is concentrated into about 2L, regulates pH value to 1～2,90 ℃ insulation, leaves standstill 5 hours with hydrochloric acid, filter, precipitation is washed till pH value to 5～6 with suitable quantity of water, 50～95% ethanol successively, and drying promptly gets Radix Scutellariae extract.
Said extracted thing micronization, join in the PEG-6000 fused solution, stirring and evenly mixing is made 10000 drop pill in the drop pill machine, adopt the HPLC method to measure content of effective, every ball contains baicalin 3.5mg, emodin and chrysophanol total amount 0.31mg, berberine 1.5mg.
The drug combination preparation that the present invention is above-mentioned has carried out following drug effect contrast experiment at " clearing capsule " that use with present, can show the beneficial effect that drug combination preparation of the present invention has.
One clearing capsule (control drug): a commercially available clearing capsule preparation (Chengdu Kanghong Pharmaceutical Co., Ltd produces, lot number 100704).
Trial drug I of the present invention: the capsule preparations of the foregoing description 1;
The prepared slices of Chinese crude drugs (Sichuan Province's prepared slices of Chinese crude drugs Co., Ltd) that controlled trial medicine II: embodiment 1 is used prepare controlled trial medicine II by current edition Chinese Pharmacopoeia one clearing capsule method for making.Take by weighing Rhizoma Coptidis 660g, Radix Et Rhizoma Rhei 2000g, Radix Scutellariae 1000g, decoct with water twice respectively, 1.5 hours for the first time, 1 hour for the second time, collecting decoction filtered, filtrate is concentrating under reduced pressure respectively, and dry (with embodiment 1) makes Radix Scutellariae extract and Radix Et Rhizoma Rhei and Rhizoma Coptidis extract; The said extracted thing adds right amount of auxiliary materials such as starch, mix homogeneously, processed according to a conventional method, incapsulate, make 1000, every dress 0.5g, adopt the HPLC method to measure content of effective, every capsules contains baicalin 33.8mg, emodin and chrysophanol total amount 1.1mg, berberine 12mg.
Trial drug III of the present invention: the capsule preparations of embodiment 2;
Trial drug IV of the present invention: the extract of embodiment 3.
1, antiinflammatory test
Xylol causes the influence of mice ear:
Getting body weight is the male mice random packet of 23-26 gram, every group 10, irritate stomach respectively and give high dose (10g crude drug/kg) and low dosage (control drug, trial drug I-IV and the equivalent distilled water (matched group) of 5g crude drug/kg), once a day, continuous three days, only evenly be coated with dimethylbenzene 0.005ml/ for animal left side ear in 40 minutes after the last administration, causing scorching back 30 minutes execution animals, with diameter is that the rustless steel punching pin of 8mm takes off left and right sides same area auricle, weigh, be calculated as follows swelling degree and inhibitory rate of intumesce, the result is as shown in table 1.
Swelling degree=(left auricle weight-auris dextra sheet is heavy)
Table 1 xylol cause mice ear influence (n=10,
)
Compare with matched group
*P＜0.05,
*P＜0.01.
Table 1 result shows, the high dose group of the high/low dosage group of trial drug I, III, IV and a clearing capsule, trial drug II all has obvious or significant antiinflammatory action, with matched group significant difference is arranged relatively, and the antiinflammatory action of trial drug of the present invention obviously is better than a clearing capsule.Result of the test simultaneously also shows that Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae adopt the 0-80% ethanol extraction respectively, can not produce obvious influence or unfavorable interference to the antiinflammatory action of drug combination preparation of the present invention.
2, interior resisting virus test
Measure LD through trial test
50After carry out formal test.Get male and female half and half mice random packet, 10 every group.Each group began to irritate stomach in preceding 1 day and gives high dose (10g crude drug/kg) and low dosage (control drug, trial drug I-IV, ribavirin 75mg/kg and the equivalent distilled water (normal control group, virus control group) of 5g crude drug/kg), continuous 5 days respectively at infecting.Except that the normal control group, all the other respectively organize mice under the ether light anaesthesia, collunarium influenza virus infection FM1 strain, and inoculum concentration is 15LD
50, infect and respectively organized mice in back 4 days and weigh, take off cervical vertebra and put to death, dissect, get lung and weigh, calculate each Mus lung exponential quantity and administration group with respect to infection group and viral infection group lung index suppression ratio, result of the test is as shown in table 2.
The influence of table 2 pair mice influenza virus property pneumonia (n=10,
)
Compare with the normal control group
▲Compare with the virus control group P＜0.001
*P＜0.01,
* *P＜0.001.
The result of table 2 shows, the high dose group of the high/low dosage group of ribavirin group and trial drug I, III, IV and a clearing capsule, trial drug II all has significant resisiting influenza virus effect, with the virus control group significant difference is arranged relatively, and the resisiting influenza virus effect of trial drug of the present invention obviously is better than a clearing capsule.Result of the test simultaneously also shows that Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae adopt the 0-80% ethanol extraction respectively, can not produce obvious influence or unfavorable interference to the resisiting influenza virus effect of drug combination preparation of the present invention.
3, rush down test down
Get 110 of healthy mices, male and female half and half are divided into 11 groups at random, 10 every group (seeing Table 3).Except that blank group is irritated stomach (ig) distilled water, all the other each groups are irritated stomach respectively and are given high dose (20g crude drug/kg) and low dosage (10g crude drug/control drug kg), trial drug I-IV, every day 1 time, continuous 2 days.After water 20-24h. is can't help in fasting then, the corresponding charcoal of ig end suspendible medicinal liquid (containing charcoal end 0.1g/ml), blank group ig charcoal end solution (0.1g/ml), pick up counting this moment, each Mus is placed in observes in the little mouse cage that is covered with filter paper.Write down the time that it melena occurs, quantity, character and the light stool of row's melena are infected with the situation of anus.Continue to observe 4h., the result is carried out statistical procedures, the results are shown in Table 3.
The influence of table 3 pair normal mouse defecation time and quantity (n=10,
)
Compare with the blank group
*P＜0.05,
*P＜0.01,
* *P＜0.001
The result of the test of table 3 shows: compare with the blank group, the control drug group of high dose and low dosage, trial drug I-IV group can significantly shorten the time of arranging melena first and increase defecation quantity, and the discharge function of trial drug group of the present invention obviously is better than a clearing capsule.Result of the test simultaneously also shows that Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae adopt the 0-80% ethanol extraction respectively, can not produce obvious influence or unfavorable interference to the discharge function of drug combination preparation of the present invention.
Above-mentioned comparative test result proves, the drug combination preparation that the present invention proposes aspect comprehensive antiinflammatory, antiviral and discharge function, obviously is better than a clearing capsule control drug of having used at present, and when saving natural pharmaceutical resources greatly, also improved curative effect.
Claims (11)
1. the pharmaceutical preparation that has clearing away heat-fire detoxifcation and blood stasis dispelling cooling blood for hemostasis effect, it is characterized in that the effective medicinal ingredient in every pharmaceutical units preparation is the Rhizoma Coptidis extract by 0.33～0.033g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 1～0.1g Radix Et Rhizoma Rhei, 0.5 the Radix Scutellariae extract of～0.05g Radix Scutellariae, and Rhizoma Coptidis, Radix Et Rhizoma Rhei, the part by weight of Radix Scutellariae is 0.66: 2: 1, and 6.0% of the weight of effective ingredient baicalin in this unit formulation 〉=its Radix Scutellariae weight, 0.10% of the total amount of emodin and chrysophanol 〉=its Radix Et Rhizoma Rhei weight, 3.03% of the weight of berberine 〉=its Rhizoma Coptidis weight is formed jointly with the auxiliary adding ingredient of acceptable in the medicine.
2. pharmaceutical preparation as claimed in claim 1, it is characterized in that the effective medicinal ingredient in said every pharmaceutical units preparation is by the Rhizoma Coptidis extract of 0.33g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 1g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.5g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=30mg, emodin and chrysophanol total amount 〉=1.0mg, berberine 〉=10mg.
3. pharmaceutical preparation as claimed in claim 1, it is characterized in that the effective medicinal ingredient in said every pharmaceutical units preparation is by the Rhizoma Coptidis extract of 0.165g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 0.5g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.25g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=15mg, emodin and chrysophanol total amount 〉=0.5mg, berberine 〉=5mg.
4. pharmaceutical preparation as claimed in claim 1, it is characterized in that the effective medicinal ingredient in said every pharmaceutical units preparation is by the Rhizoma Coptidis extract of 0.066g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 0.2g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.1g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=6mg, emodin and chrysophanol total amount 〉=0.2mg, berberine 〉=2mg.
5. pharmaceutical preparation as claimed in claim 1, it is characterized in that the effective medicinal ingredient in said every pharmaceutical units preparation is by the Rhizoma Coptidis extract of 0.033g Rhizoma Coptidis, the Radix Et Rhizoma Rhei extract of 0.1g Radix Et Rhizoma Rhei, the Radix Scutellariae extract of 0.05g Radix Scutellariae, and wherein said effective ingredient baicalin 〉=3mg, emodin and chrysophanol total amount 〉=0.1mg, berberine 〉=1mg.
6. as the described pharmaceutical preparation of one of claim 1 to 5, it is characterized in that said preparation is the Peroral solid dosage form type pharmaceutical preparation that comprises tablet, capsule, soft capsule, drop pill.
7. as the described pharmaceutical preparation of one of claim 1 to 5, it is characterized in that said effective medicinal ingredient is 0～80% ethanol-water mixed solvent for contain pure ratio with volume, after the Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae that pulverize separately is crossed the said proportional quantities of 5～60 mesh sieves extracted, through concentrating under reduced pressure and exsiccant extract.
8. pharmaceutical preparation as claimed in claim 7, it is characterized in that said effective medicinal ingredient is 50～80% ethanol for contain pure ratio with volume, after the Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae that pulverize separately is crossed the said proportional quantities of 5～60 mesh sieves extracted, through concentrating under reduced pressure and exsiccant extract.
9. pharmaceutical preparation as claimed in claim 7, it is characterized in that said effective medicinal ingredient for respectively to Rhizoma Coptidis, Radix Et Rhizoma Rhei, Radix Scutellariae with said extraction solvent heating and refluxing extraction 2～3 times, each 0.5～2 hour, merge extractive liquid,, filter, filtrate is respectively through concentrating under reduced pressure and dry Radix Scutellariae extract, Radix Et Rhizoma Rhei extract and the Rhizoma Coptidis extract that obtains.
10. pharmaceutical preparation as claimed in claim 7, it is characterized in that said effective medicinal ingredient Radix Scutellariae extract, for with the pulverizing Radix Scutellariae water boiling and extraction of said proportional quantities 2～3 times, each 0.5～2 hour, collecting decoction filters, and hydrochloric acid is regulated pH value to 1～2 behind the concentrating under reduced pressure, leaves standstill 2-12 hour in 70～90 ℃, filter, precipitate the extract that water, ethanol successively are washed till pH value to 5～7 after drying.
11. pharmaceutical preparation as claimed in claim 7, it is characterized in that said effective medicinal ingredient Rhizoma Coptidis extract and Radix Et Rhizoma Rhei extract, after Rhizoma Coptidis and Radix Et Rhizoma Rhei after the pulverizing of said proportional quantities are extracted with 0～80% ethanol-water solution percolation respectively, collect percolate, concentrating under reduced pressure and dried extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110089276 CN102178753B (en) | 2011-04-11 | 2011-04-11 | Medicinal preparation with effects of clearing heat, purging intense heat, detoxifying, eliminating blood stasis, cooling blood and stopping bleeding |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110089276 CN102178753B (en) | 2011-04-11 | 2011-04-11 | Medicinal preparation with effects of clearing heat, purging intense heat, detoxifying, eliminating blood stasis, cooling blood and stopping bleeding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102178753A true CN102178753A (en) | 2011-09-14 |
| CN102178753B CN102178753B (en) | 2012-08-15 |
Family
ID=44565159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110089276 Active CN102178753B (en) | 2011-04-11 | 2011-04-11 | Medicinal preparation with effects of clearing heat, purging intense heat, detoxifying, eliminating blood stasis, cooling blood and stopping bleeding |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102178753B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103163260A (en) * | 2011-12-16 | 2013-06-19 | 成都康弘制药有限公司 | Fingerprints of drugs and determination method thereof |
| CN105267325A (en) * | 2014-05-28 | 2016-01-27 | 成都康弘制药有限公司 | Applications of pharmaceutical composition in preparation of influenza A virus infection prevention and treatment drugs |
| CN105267327A (en) * | 2015-11-30 | 2016-01-27 | 陕西东泰制药有限公司 | Traditional Chinese medicine composition for clearing heat, removing toxicity, removing blood stasis and cooling blood and preparation method thereof |
| CN108853358A (en) * | 2018-08-20 | 2018-11-23 | 西南交通大学 | A kind of antibacterial Chinese medicine composition and its preparation method and application |
| CN110772566A (en) * | 2019-11-07 | 2020-02-11 | 辽宁康博士制药有限公司 | Traditional Chinese medicine composition for clearing heat and purging fire and preparation method thereof |
| CN113368161A (en) * | 2021-05-27 | 2021-09-10 | 成都中医药大学 | Method for recycling clear capsule medicine dregs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890087A (en) * | 2010-07-27 | 2010-11-24 | 李钢 | Composition containing coptis root, rhubarb and baikal skullcap root |
-
2011
- 2011-04-11 CN CN 201110089276 patent/CN102178753B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890087A (en) * | 2010-07-27 | 2010-11-24 | 李钢 | Composition containing coptis root, rhubarb and baikal skullcap root |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103163260A (en) * | 2011-12-16 | 2013-06-19 | 成都康弘制药有限公司 | Fingerprints of drugs and determination method thereof |
| CN103163260B (en) * | 2011-12-16 | 2014-12-24 | 成都康弘制药有限公司 | Determination method of fingerprints of drugs |
| CN105267325A (en) * | 2014-05-28 | 2016-01-27 | 成都康弘制药有限公司 | Applications of pharmaceutical composition in preparation of influenza A virus infection prevention and treatment drugs |
| CN105267325B (en) * | 2014-05-28 | 2019-10-29 | 成都康弘制药有限公司 | Pharmaceutical composition controls the application in influenza a virus infection drug in preparation in advance |
| CN105267327A (en) * | 2015-11-30 | 2016-01-27 | 陕西东泰制药有限公司 | Traditional Chinese medicine composition for clearing heat, removing toxicity, removing blood stasis and cooling blood and preparation method thereof |
| CN108853358A (en) * | 2018-08-20 | 2018-11-23 | 西南交通大学 | A kind of antibacterial Chinese medicine composition and its preparation method and application |
| CN108853358B (en) * | 2018-08-20 | 2021-06-01 | 西南交通大学 | Antibacterial traditional Chinese medicine composition and preparation method and application thereof |
| CN110772566A (en) * | 2019-11-07 | 2020-02-11 | 辽宁康博士制药有限公司 | Traditional Chinese medicine composition for clearing heat and purging fire and preparation method thereof |
| CN113368161A (en) * | 2021-05-27 | 2021-09-10 | 成都中医药大学 | Method for recycling clear capsule medicine dregs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102178753B (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178753B (en) | Medicinal preparation with effects of clearing heat, purging intense heat, detoxifying, eliminating blood stasis, cooling blood and stopping bleeding | |
| CN100542585C (en) | A kind of externally-applied medicinal composition with analgesia and antiinflammatory action | |
| CN102068480A (en) | Edible and medicinal compound preparation with effects of heatstroke alleviation and detoxification | |
| CN104983844A (en) | Edible composition formula with mucous-membrane restoring function and preparation process of preparation thereof | |
| CN1970032B (en) | Chinese medicine containing honeysuckle flower and weeping forsythia for treating cold | |
| CN100473394C (en) | Compound preparation of baikal skullcap root | |
| CN100386071C (en) | Medicine for treating cough and chronic bronchitis | |
| CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
| CN101703690B (en) | Medicament for treating metrorrhagia and metrostaxis, hematemesis, hematochezia and traumatic hemorrhage and preparation method thereof | |
| CN103239507A (en) | Medicinal composition capable of being rapidly disintegrated and dissolved in oral cavity and preparation method thereof | |
| CN100434065C (en) | Hemostatic preparation for gynecology department | |
| CN101406629A (en) | Buccal tablets for treating painful swelling of gingiva and preparation method thereof | |
| KR20040060808A (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| CN100370993C (en) | Medicinal composition with heat-clearing, fire-draining and detoxification function | |
| CN101066355B (en) | Chinese medicine prepn for treating toothache and its prepn process | |
| CN100509017C (en) | Medicine for treating biliary tract infection and prepn process thereof | |
| CN100367938C (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| CN107854671A (en) | A Na series anaesthetic intragastric floating sustained-release preparations and preparation method thereof | |
| CN100336502C (en) | Yunnan Manyleaf paris Rhizome extract ora disintegration tablet and its preparing process | |
| CN100548326C (en) | A kind of Chinese medicine composition of protecting gastric mucosa and preparation method thereof | |
| CN101239145A (en) | 'Gualou Xiebai Guizhi' oral preparation and preparation thereof | |
| CN102247515B (en) | Traditional Chinese medicine compound preparation used for treating diabetic nephropathy, and preparation method thereof | |
| CN113058013A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament | |
| CN110302166A (en) | A kind of swap buffers tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190619 Address after: 618500 No. 13 Xingye Avenue, Chengnan Industrial Park, Luojiang Economic Development Zone, Sichuan Province Patentee after: SICHUAN XIAOYE HERBARY BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 610041 No. 51, Fourth Section of Renmin South Road, Chengdu City, Sichuan Province Patentee before: Sichuan Academy of Chinese Medicine Sciences |